Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
Healthcare
$3.12 +1.42%
+$0.06 today
- Market cap
- $184.11M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
52W Low $1.57High $5.50
Volume 0.40M
Average 0.31M
Income Statement
Follow revenue through to earnings.
Revenue
$7.14M
FY 2025 · Annual
-72.5% YoYOperating Income
-$114.40M
FY 2025 · Annual
Net Income
-$20.60M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.12M | 15.22M | 24.35M | 25.98M | 7.15M |
| Cost of Revenue | 19.67M | 34M | 51.74M | 54.05M | 760K |
| Gross Profit | (18.55M) | (18.78M) | (27.38M) | (28.07M) | 6.39M |
| Gross Margin | -1656.3% | -123.4% | -112.4% | -108.0% | 89.4% |
| Research & Development | 19.67M | 32.66M | 48.93M | 51.03M | 90.96M |
| Selling, General & Admin | 18.51M | 40.18M | 44.55M | 36.75M | 29.82M |
| Operating Expenses | 92.67M | 43.9M | 44.55M | 39.39M | 120.79M |
| Depreciation & Amortization | 105K | 159K | 169K | 193K | 79K |
| EBITDA | (36.96M) | (58.8M) | (65.37M) | (64.63M) | (20.52M) |
| EBITDA Margin | -3299.6% | -386.4% | -268.4% | -248.7% | -287.2% |
| Operating Income | (111.22M) | (62.68M) | (71.93M) | (67.46M) | (114.4M) |
| Operating Margin | -9930.1% | -411.9% | -295.4% | -259.6% | -1601.1% |
| Interest Income | 13K | 2.4M | 6.4M | 3.93M | 6.23M |
| Interest Expense | 665K | 230K | 231K | 154K | 0 |
| Other Income / Expenses | 1.13M | 2.17M | 6.17M | 3.77M | 93.8M |
| Income Before Tax | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Pre-Tax Margin | -9829.3% | -397.7% | -270.0% | -245.1% | -288.3% |
| Income Tax Expense | 2K | 0 | 0 | 0 | 0 |
| Net Income | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Net Margin | -9829.5% | -397.7% | -270.0% | -245.1% | -288.3% |
| EPS (Basic) | (12.41) | (2.69) | (2.44) | (2.36) | (0.33) |
| EPS (Diluted) | (12.41) | (2.69) | (2.44) | (2.36) | (0.33) |
| 8.87M | 22.51M | 26.92M | 27.03M | 61.89M | |
| 8.92M | 22.51M | 26.92M | 27.03M | 61.89M |
WHWK Earnings Waterfall · TTM
NASDAQ:WHWK · Revenue to Net Income
Key Ratios
EPS$-1.68
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$115.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.68, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| DEFA14A | DEFA14A filing | Apr 28, 2026 | |
| ARS | ARS filing | Apr 28, 2026 |
How much revenue does WHWK generate?
Whitehawk Therapeutics Inc (WHWK) reported $7.14M of revenue in fiscal 2025.
Is WHWK profitable?
Whitehawk Therapeutics Inc (WHWK) reported -$20.60M of net income, with a net margin of -288.3%.
Continue the stock analysis
Jump to another research area for this company.